510(k) SUMMARY

1. Applicant Information

Applicant Name:

Collagen Matrix, Inc.

Address:

15 Thornton Road

Oakland, New Jersey 07436

Telephone:

(201) 405-1477 (201) 405-1355

Fax:

Peggy Hansen, RAC

Contact Person:

VP, Clinical, Regulatory, QA, and Marketing

Date Prepared:

October 4, 2012

2. Name of the Device

Device Common Name:

Collagen Wound Dressing

Device Trade Name:

Collagen Dental Wound Dressings

Device Classification Name:

Dressing, Wound, Collagen

KGN

Unclassified

3. Legally Marketed Devices to Which Substantial Equivalence is Claimed

Predicate Device(s):

Collacare Dental, Collagen Dental Matrix

K110388

Collagen Wound Dressing - Oral

K040403

4. Description of the Device

Collagen Dental Wound Dressings are absorbent, porous, collagen matrices engineered from highly purified type I collagen derived from porcine Achilles tendon. The Collagen Dental Wound Dressings are applied directly to the wound and protect the wound and delicate new tissue. Collagen Dental Wound Dressings are supplied sterile, non-pyrogenic, in various sizes, and for single use only.

5. Intended Use

Collagen Dental Wound Dressings are intended for the management of oral wounds and sores, including:

- Denture sores
- Oral ulcers (non-infected or viral)
- Periodontal surgical wounds
- Suture sites

Collagen Matrix, Inc. 510(k) Summary Collagen Dental Wound Dressings

- Burns
- Extraction sites
- Surgical wounds
- Traumatic wounds

6. Summary/Comparison of Technical Characteristics

Collagen Dental Wound Dressings and their predicates have similar technological characteristics. In particular, the Collagen Dental Wound Dressings and the predicates are similar with respect to intended use, purified starting material (type I collagen), form, sizes, physical integrity. The substantial equivalence of Collagen Dental Wound Dressings and their predicates was demonstrated based on in vitro characterization studies, biocompatibility studies, and clinical history of the predicate devices.

In vitro characterization studies included evaluation of material properties, biological properties, chemical and physical properties.

Collagen Dental Wound Dressing representative products have been evaluated in a number of in vitro and in vivo tests to assess its safety/biocompatibility. The products passed all applicable FDA Blue Book Memorandum G95-1 and ISO 10993-1 testing for the biological evaluation of medical devices. No clinical tests were performed on the product, however clinical history of the predicate device was referenced in the submission.

Viral inactivation studies were performed to ensure the viral safety of the product.

Conclusion of Non-clinical Studies

The results of the *in vitro* product characterization studies as well as *in vitro* and *in vivo* biocompatibility studies show that Collagen Dental Wound Dressings are safe and substantially equivalent to the predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Collagen Matrix, Incorporated Ms. Peggy Hansen, RAC Vice President, Clinical, Regulatory, Quality Assurance, & Marketing 15 Thornton Road Oakland, New Jersey 07436 NOV

1 2012

Re: K122115

Trade/Device Name: Collagen Dental Wound Dressings

Regulation Number: Unclassified

Regulation Name: Dressing, Wound, Collagen

Regulatory Class: Unclassified

Product Code: KGN
Dated: October 4, 2012
Received: October 5, 2012

Dear Ms. Hansen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

The for

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Office of Device Evaluat Center for Devices and

Radiological Health

Indications for Use

510(k) Number (if known):	
Device Name: Collagen Dental Wou	und Dressings
Indications for Use:	
sores, including:	nded for the management of oral wounds and
 Denture sores Oral ulcers (non-infected or viral) Periodontal surgical wounds Suture sites Burns 	
 Extraction sites Surgical wounds Traumatic wounds 	
,	, , , , , , , , , , , , , , , , , , ,
Prescription Use X AND/ (Part 21 CFR 801 Subpart D)	OR Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS NEEDED)	LINE – CONTINUE ON ANOTHER PAGE IF
Concurrence of CDRH, Office of Device Evaluation (ODE)	
Susan Punpe	• •••
(Division Sign-Off) Division of Anesthesiclogy, General Hose Infection Control, Dental Devices	Page 1 of _1
510(k) Number: 1000 10	